INS and metabolic dysfunction-associated steatotic liver disease: As discussed in a recent review by Zelber-Sagi et al., the plausible biological mechanisms for this beneficial effect include the reduction of insulin resistance [18], although in our study, we found no change in glycemia, insulin level, and HOMA-IR among NAFLD patients, during the intervention period.